List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8084465/publications.pdf Version: 2024-02-01

		25423	46524
237	11,374	59	93
papers	citations	h-index	g-index
0.41	0.41	0.41	1 4700
241	241	241	14/30
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications. Seminars in Cancer Biology, 2022, 83, 152-165.	4.3	37
2	Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway. Seminars in Cancer Biology, 2022, 83, 177-196.	4.3	21
3	Role of non-coding RNAs in the progression and resistance of cutaneous malignancies and autoimmune diseases. Seminars in Cancer Biology, 2022, 83, 208-226.	4.3	16
4	Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: Micromanaging by not so small non-coding RNAs. Seminars in Cancer Biology, 2022, 85, 155-163.	4.3	41
5	Natural resorcylic acid lactones: A chemical biology approach for anticancer activity. Drug Discovery Today, 2022, 27, 547-557.	3.2	13
6	The potential role of vitamin C in empowering cancer immunotherapy. Biomedicine and Pharmacotherapy, 2022, 146, 112553.	2.5	24
7	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Annals of Medicine, 2022, 54, 524-540.	1.5	225
8	Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. Seminars in Cancer Biology, 2022, 86, 382-399.	4.3	21
9	Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 99.	3.5	44
10	Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression. Seminars in Cancer Biology, 2022, 86, 697-708.	4.3	15
11	Anticancer activity of Neosetophomone B by targeting AKT/SKP2/MTH1 axis in leukemic cells. Biochemical and Biophysical Research Communications, 2022, 601, 59-64.	1.0	7
12	The Incidence and Determinants of Metabolic Syndrome Amongst a Group of Migrants to Qatar: A Prospective Longitudinal Observational Cohort Study 24-Months Post-Migration. Journal of Clinical Medicine, 2022, 11, 34.	1.0	2
13	Aryl hydrocarbon Receptor (AhR) Promotes Cell Growth, Induces Stemness Like Characteristics and Metastasis in Ovarian Cancer Cells via Activation of Akt, β atenin and EMT. FASEB Journal, 2022, 36, .	0.2	1
14	Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis. Cancer and Metastasis Reviews, 2022, 41, 281-299.	2.7	16
15	Aryl Hydrocarbon Receptor Promotes Cell Growth, Stemness Like Characteristics, and Metastasis in Human Ovarian Cancer via Activation of PI3K/Akt, β-Catenin, and Epithelial to Mesenchymal Transition Pathways. International Journal of Molecular Sciences, 2022, 23, 6395.	1.8	13
16	Prospective Role of Bioactive Molecules and Exosomes in the Therapeutic Potential of Camel Milk against Human Diseases: An Updated Perspective. Life, 2022, 12, 990.	1.1	3
17	Therapeutic Effects of Curcumol in Several Diseases; An Overview. Nutrition and Cancer, 2021, 73, 181-195.	0.9	39
18	Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Molecular Cancer, 2021, 20, 2.	7.9	76

#	Article	IF	CITATIONS
19	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74.	3.5	19
20	Anticancer Activity of Natural Compounds. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1-2.	0.5	5
21	Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 617281.	1.8	53
22	F-box proteins in cancer stemness: An emerging prognostic and therapeutic target. Drug Discovery Today, 2021, 26, 2905-2914.	3.2	10
23	The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Tumor Biology, 2021, 43, 177-196.	0.8	5
24	The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. Cancer and Metastasis Reviews, 2021, 40, 691-720.	2.7	33
25	Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells. Leukemia and Lymphoma, 2021, 62, 3170-3180.	0.6	7
26	The role of PAK4 in the immune system and its potential implication in cancer immunotherapy. Cellular Immunology, 2021, 367, 104408.	1.4	11
27	Anti-cancer effects of Tranilast: An update. Biomedicine and Pharmacotherapy, 2021, 141, 111844.	2.5	18
28	Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomedicine and Pharmacotherapy, 2021, 143, 112142.	2.5	50
29	Anticancer Activity of Neosetophomone B, An Aquatic Fungal Secondary Metabolite, Against Hematological Malignancie S. , 2021, , .		О
30	Sanguinarine mediated apoptosis in Non-Small Cell Lung Cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway. Biomedicine and Pharmacotherapy, 2021, 144, 112358.	2.5	25
31	17â€Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients. , 2021, 9, A19-A19.		1
32	736â€Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer. , 2021, 9, A767-A767.		0
33	The effect of migration on the incidence of new-onset metabolic syndrome in migrants to Qatar. Journal of Emergency Medicine, Trauma and Acute Care, 2021, 2021, .	0.1	0
34	Editorial: LncRNAs in Cancer Metastasis and Therapy Resistance. Frontiers in Oncology, 2021, 11, 813274.	1.3	4
35	Development of a Critical Appraisal Tool (AIMRDA) for the Peer-Review of Studies Assessing the Anticancer Activity of Natural Products: A Step towards Reproducibility. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3735-3740.	0.5	1
36	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin. Frontiers in Oncology, 2020, 10, 1744.	1.3	14

#	Article	IF	CITATIONS
37	Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells. Journal of Pharmacy and Pharmacology, 2020, 72, 1536-1545.	1.2	9
38	Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5002.	1.8	15
39	Recent developments in unraveling signaling mechanisms underlying drug resistance due to cancer stem-like cells. Current Opinion in Pharmacology, 2020, 54, 130-141.	1.7	8
40	Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B. European Journal of Pharmacology, 2020, 888, 173420.	1.7	6
41	Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report. , 2020, 8, e001278.		9
42	TRPV2: A Cancer Biomarker and Potential Therapeutic Target. Disease Markers, 2020, 2020, 1-10.	0.6	42
43	Exosomes: Emerging Diagnostic and Therapeutic Targets in Cutaneous Diseases. International Journal of Molecular Sciences, 2020, 21, 9264.	1.8	18
44	Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers, 2020, 12, 1172.	1.7	80
45	Prevalence and Type Distribution of High-Risk Human Papillomavirus (HPV) in Breast Cancer: A Qatar Based Study. Cancers, 2020, 12, 1528.	1.7	19
46	CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. International Journal of Molecular Sciences, 2020, 21, 3906.	1.8	50
47	Sanguinarine Induces Apoptosis in Papillary Thyroid Cancer Cells via Generation of Reactive Oxygen Species. Molecules, 2020, 25, 1229.	1.7	17
48	Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Molecular Cancer, 2020, 19, 57.	7.9	68
49	Genetic and Neuroimaging Approaches to Understanding Post-Traumatic Stress Disorder. International Journal of Molecular Sciences, 2020, 21, 4503.	1.8	21
50	Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells. Cancers, 2020, 12, 351.	1.7	30
51	Urine as a Main Effector in Urological Tissue Engineering—A Double-Edged Sword. Cells, 2020, 9, 538.	1.8	26
52	Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 438.	1.8	57
53	Claudin-1, A Double-Edged Sword in Cancer. International Journal of Molecular Sciences, 2020, 21, 569.	1.8	76
54	Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. Journal of Translational Medicine, 2020, 18, 140.	1.8	59

#	Article	IF	CITATIONS
55	Immunogenetics of Celiac Disease: A Focus on Arab Countries. Current Molecular Medicine, 2020, 20, 275-285.	0.6	7
56	Functional In Vivo Imaging of Tumors. Cancer Treatment and Research, 2020, 180, 3-50.	0.2	1
57	Understanding Checkpoint Inhibitors in Cancer Therapy, Mechanisms of Action, Resistance and Future Challenges. Clinical Oncology and Research, 2020, , 1-13.	0.1	2
58	Sanguinarine Mediated Anti-Tumor activity Via Targeting JAK/STAT3 Pathway in Thyroid Cancer. , 2020, , .		0
59	463â€Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno-modulatory markers. , 2020, , .		0
60	Curcumin Induces Apoptotic Cell Death via Inhibition of PI3-Kinase/AKT Pathway in B-Precursor Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2019, 9, 484.	1.3	56
61	Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. Cells, 2019, 8, 840.	1.8	195
62	Protein Expression Profiling Identifies Key Proteins and Pathways Involved in Growth Inhibitory Effects Exerted by Guggulsterone in Human Colorectal Cancer Cells. Cancers, 2019, 11, 1478.	1.7	16
63	The Role of Extracellular Vesicles as Modulators of the Tumor Microenvironment, Metastasis and Drug Resistance in Colorectal Cancer. Cancers, 2019, 11, 746.	1.7	42
64	Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling. Frontiers in Oncology, 2019, 9, 285.	1.3	31
65	Role of animal research in human malignancies. , 2019, , 1-29.		3
66	Role of 3D tissue engineering models for human cancer and drug development. , 2019, , 309-322.		3
67	Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. Scientific Reports, 2019, 9, 1554.	1.6	18
68	Greensporone A, a Fungal Secondary Metabolite Suppressed Constitutively Activated AKT via ROS Generation and Induced Apoptosis in Leukemic Cell Lines. Biomolecules, 2019, 9, 126.	1.8	13
69	Oncogenic role of dysregulated leptin signaling in the pathogenesis of ovarian cancer. Translational Medicine Communications, 2019, 4, .	0.5	3
70	Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Molecular Cancer, 2019, 18, 55.	7.9	304
71	Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 782-794.	0.6	29
72	RAS-mediated oncogenic signaling pathways in human malignancies. Seminars in Cancer Biology, 2019, 54, 1-13.	4.3	115

#	Article	IF	CITATIONS
73	Association of genes with phenotype in autism spectrum disorder. Aging, 2019, 11, 10742-10770.	1.4	23
74	Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, S22-S22.	0.7	2
75	5-AZA treatment induces cytotoxicity and in vitro expression of immunogenic NY-ESO-1 antigen in non-small lung cancer cell NCI-H1975. Annals of Oncology, 2019, 30, xi14-xi15.	0.6	0
76	Embelin: a benzoquinone possesses therapeutic potential for the treatment of human cancer. Future Medicinal Chemistry, 2018, 10, 961-976.	1.1	29
77	Dysregulated expression of SKP2 and its role in hematological malignancies. Leukemia and Lymphoma, 2018, 59, 1051-1063.	0.6	16
78	PD-L1 blockade during ex vivo expansion of virus-specific T cells for the treatment of infections after allogeneic hematopoietic stem cell transplantation modulates the phenotype and functional activity of T cells. Annals of Oncology, 2018, 29, x14-x15.	0.6	0
79	Curcumin-Mediated Degradation of S-Phase Kinase Protein 2 Induces Cytotoxic Effects in Human Papillomavirus-Positive and Negative Squamous Carcinoma Cells. Frontiers in Oncology, 2018, 8, 399.	1.3	19
80	Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. Cancer Letters, 2018, 430, 133-147.	3.2	54
81	Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target. Frontiers in Oncology, 2018, 8, 257.	1.3	32
82	Greensporone C, a Freshwater Fungal Secondary Metabolite Induces Mitochondrial-Mediated Apoptotic Cell Death in Leukemic Cell Lines. Frontiers in Pharmacology, 2018, 9, 720.	1.6	23
83	Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. Molecular Cancer, 2018, 17, 31.	7.9	79
84	Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. Journal of Translational Medicine, 2018, 16, 96.	1.8	133
85	Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. Frontiers in Immunology, 2018, 9, 1769.	2.2	15
86	Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk. Frontiers in Physiology, 2018, 9, 1942.	1.3	252
87	Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3501-3509.	0.5	28
88	Targeting acute myeloid leukemia stem cell signaling by natural products. Molecular Cancer, 2017, 16, 13.	7.9	104
89	Potential therapeutic targets of Guggulsterone in cancer. Nutrition and Metabolism, 2017, 14, 23.	1.3	31
90	Anticancer potential of sanguinarine for various human malignancies. Future Medicinal Chemistry, 2017, 9, 933-950.	1.1	45

6

#	Article	IF	CITATIONS
91	Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells. PLoS ONE, 2017, 12, e0180895.	1.1	36
92	Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. Current Vascular Pharmacology, 2017, 15, 339-351.	0.8	143
93	An Overview of Proteomics Techniques and its Application as a Tool in Biomarker and Drug Discovery. Journal of Proteomics & Enzymology, 2017, 06, .	0.5	1
94	Therapeutic Potential of Resveratrol in Lymphoid Malignancies. Nutrition and Cancer, 2016, 68, 365-373.	0.9	13
95	Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. Journal of Translational Medicine, 2016, 14, 69.	1.8	36
96	Involvement of F-BOX proteins in progression and development of human malignancies. Seminars in Cancer Biology, 2016, 36, 18-32.	4.3	48
97	Role of leptin and leptin receptors in hematological malignancies. Leukemia and Lymphoma, 2016, 57, 10-16.	0.6	14
98	Pristimerin Inhibits Growth and Induces Apoptosis in Human Colorectal Cancer Cells Through the Generation of Reactive Oxygen Species. , 2016, , .		0
99	Bortezomib Mediated Downregulation of F-box Protein, S-phase Kinase-Associated Protein 2 (SKP2) Causes Apoptotic Cell Death in Chronic Myelogenous Leukemia Cells. , 2016, , .		0
100	Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. Cancer, 2015, 121, 3799-3808.	2.0	19
101	Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer. Molecular Medicine, 2015, 21, 466-478.	1.9	10
102	Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer. Cancer, 2015, 121, 1762-1771.	2.0	34
103	Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E974-E985.	1.8	34
104	Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Molecular Cancer, 2015, 14, 131.	7.9	33
105	High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis, 2014, 35, 1564-1572.	1.3	40
106	Role of dysregulated expression of leptin and leptin receptors in colorectal carcinogenesis. Tumor Biology, 2014, 35, 871-879.	0.8	17
107	A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Molecular Cancer, 2014, 13, 168.	7.9	31
108	Bortezomib inhibits proteasomal degradation of lκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2014, 55, 415-424.	0.6	25

#	Article	IF	CITATIONS
109	ALK gene amplification is associated with poor prognosis in colorectal carcinoma. British Journal of Cancer, 2013, 109, 2735-2743.	2.9	32
110	Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine, 2013, 61, 329-335.	1.4	8
111	Phosphorylated lκBα Predicts Poor Prognosis in Activated B-Cell Lymphoma and Its Inhibition with Thymoquinone Induces Apoptosis via ROS Release. PLoS ONE, 2013, 8, e60540.	1.1	26
112	Constitutional Mismatch Repair-Deficiency Syndrome Is a Rare Cause of Cancer Even in a Highly Consanguineous Population. Journal of Cancer Therapy, 2013, 04, 996-1004.	0.1	1
113	In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment. Current Medicinal Chemistry, 2012, 19, 3730-3738.	1.2	24
114	Colorectal cancer risk is not associated with increased levels of homozygosity in Saudi Arabia. Genetics in Medicine, 2012, 14, 720-728.	1.1	14
115	FoxM1 and Its Association with Matrix Metalloproteinases (MMP) Signaling Pathway in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1-E13.	1.8	56
116	Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica, 2012, 97, 1092-1100.	1.7	41
117	Role of nuclear factor-l̂ºB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 1971-1977.	0.6	16
118	Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis. PLoS ONE, 2012, 7, e39945.	1.1	138
119	c-Met Inhibitor Synergizes with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Papillary Thyroid Carcinoma Cell Death. Molecular Medicine, 2012, 18, 167-177.	1.9	13
120	Genome-Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy. American Journal of Pathology, 2011, 178, 537-547.	1.9	134
121	Bortezomib Stabilizes Mitotic Cyclins and Prevents Cell Cycle Progression via Inhibition of UBE2C in Colorectal Carcinoma. American Journal of Pathology, 2011, 178, 2109-2120.	1.9	53
122	Coexpression of Activated c-Met and Death Receptor 5 Predicts Better Survival in Colorectal Carcinoma. American Journal of Pathology, 2011, 179, 3032-3044.	1.9	8
123	Localization of death receptor 4 in lipid rafts sensitizes chronic lymphocytic leukemia to chemotherapeutic drug mediated apoptosis. Leukemia and Lymphoma, 2011, 52, 1176-1177.	0.6	2
124	Overexpression of Fatty Acid Synthase in Middle Eastern Epithelial Ovarian Carcinoma Activates AKT and Its Inhibition Potentiates Cisplatin-Induced Apoptosis. Molecular Medicine, 2011, 17, 635-645.	1.9	26
125	Resveratrol Suppresses Constitutive Activation of AKT via Generation of ROS and Induces Apoptosis in Diffuse Large B Cell Lymphoma Cell Lines. PLoS ONE, 2011, 6, e24703.	1.1	72
126	HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Laboratory Investigation, 2011, 91, 124-137.	1.7	33

#	Article	IF	CITATIONS
127	Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. Free Radical Biology and Medicine, 2011, 50, 978-987.	1.3	88
128	Clinico-pathological significance of TNF alpha-induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma. Clinical Epigenetics, 2011, 2, 417-418.	1.8	7
129	The biological and clinical impact of inhibition of NFâ€̂PBâ€initiated apoptosis in diffuse large B cell lymphoma (DLBCL). Journal of Pathology, 2011, 224, 355-366.	2.1	46
130	Demethylation of <i>TMS1</i> Gene Sensitizes Thyroid Cancer Cells to TRAIL-Induced Apoptosis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E215-E224.	1.8	19
131	MMP7 Polymorphisms - A new tool in molecular pathology to understand esophageal cancer. Saudi Journal of Gastroenterology, 2011, 17, 299.	0.5	3
132	Role of leptin and its receptors in the pathogenesis of thyroid cancer. International Journal of Clinical and Experimental Pathology, 2011, 4, 637-43.	0.5	21
133	Cyclooxygenaseâ€2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. International Journal of Cancer, 2010, 126, 382-394.	2.3	91
134	Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. Journal of Pathology, 2010, 222, 180-190.	2.1	48
135	Apigenin induces apoptosis <i>via</i> downregulation of Sâ€phase kinaseâ€associated protein 2â€mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Proliferation, 2010, 43, 170-183.	2.4	45
136	Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Laboratory Investigation, 2010, 90, 1346-1356.	1.7	33
137	Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocrine-Related Cancer, 2010, 17, 191-202.	1.6	70
138	Inhibition of Fatty Acid Synthase Suppresses c-Met Receptor Kinase and Induces Apoptosis in Diffuse Large B-Cell Lymphoma. Molecular Cancer Therapeutics, 2010, 9, 1244-1255.	1.9	40
139	Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Molecular Cancer, 2010, 9, 203.	7.9	24
140	Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2010, 51, 1305-1314.	0.6	47
141	High Prevalence of Fatty Acid Synthase Expression in Colorectal Cancers in Middle Eastern Patients and Its Potential Role as a Therapeutic Target. American Journal of Gastroenterology, 2009, 104, 1790-1801.	0.2	39
142	Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Molecular Cancer Therapeutics, 2009, 8, 615-625.	1.9	14
143	Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis, 2009, 30, 1832-1840.	1.3	52
144	Frequent <i>PIK3CA</i> gene amplification and its clinical significance in colorectal cancer. Journal of Pathology, 2009, 219, 337-346.	2.1	45

#	Article	IF	CITATIONS
145	Prognostic significance of alterations in KRAS isoforms KRASâ€4A/4B and <i>KRAS</i> mutations in colorectal carcinoma. Journal of Pathology, 2009, 219, 435-445.	2.1	78
146	Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Laboratory Investigation, 2009, 89, 1115-1127.	1.7	19
147	Developing curcumin into a viable therapeutic for lymphoma. Expert Opinion on Investigational Drugs, 2009, 18, 57-67.	1.9	7
148	PIK3CA alterations in Middle Eastern ovarian cancers. Molecular Cancer, 2009, 8, 51.	7.9	36
149	Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Molecular Cancer, 2009, 8, 74.	7.9	97
150	Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells. Leukemia and Lymphoma, 2009, 50, 1204-1213.	0.6	26
151	Inhibition of Fatty Acid Synthase Suppresses c-Met Receptor Kinase and Induces Apoptosis in Diffuse Large B Cell Lymphoma Blood, 2009, 114, 4787-4787.	0.6	1
152	Polymorphisms of selected Xenobiotic Genes contribute to the development of Papillary Thyroid Cancer susceptibility in Middle Eastern population. BMC Medical Genetics, 2008, 9, 61.	2.1	43
153	Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene, 2008, 27, 3539-3545.	2.6	85
154	Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Human Pathology, 2008, 39, 885-894.	1.1	19
155	Sphingosine kinase is an attractive target for novel pharmacological interventions in non-Hodgkin lymphomas. Leukemia and Lymphoma, 2008, 49, 850-851.	0.6	1
156	RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. Journal of Endocrinological Investigation, 2008, 31, 893-899.	1.8	55
157	Polymorphisms of drug-metabolizing enzymesCYP1A1,GSTTandGSTPcontribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leukemia and Lymphoma, 2008, 49, 122-129.	0.6	37
158	Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Molecular Cancer Therapeutics, 2008, 7, 3318-3329.	1.9	118
159	Distinct Gene Expression Profiles: Nodal versus Extranodal Diffuse Large B-Cell Lymphoma. Oncology, 2008, 75, 71-80.	0.9	19
160	Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leukemia and Lymphoma, 2008, 49, 1945-1953.	0.6	46
161	Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal Cancer. Cancer Research, 2008, 68, 3379-3388.	0.4	68
162	Clinicopathological Analysis of Papillary Thyroid Cancer with <i>PIK3CA</i> Alterations in a Middle Eastern Population. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 611-618.	1.8	169

#	Article	IF	CITATIONS
163	Fatty Acid Synthase and AKT Pathway Signaling in a Subset of Papillary Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4088-4097.	1.8	65
164	Fatty Acid Synthase and Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 4979-4979.	0.6	2
165	Colorectal carcinomas from Middle East. Molecular and tissue microarray analysis of genomic instability pathways. Journal of King Abdulaziz University, Islamic Economics, 2008, 29, 75-80.	0.5	8
166	p38 MAPK activation coupled to endocytosis is a determinant of endothelial monolayer integrity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L114-L124.	1.3	17
167	Sanguinarine-Dependent Induction of Apoptosis in Primary Effusion Lymphoma Cells. Cancer Research, 2007, 67, 3888-3897.	0.4	122
168	PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia, 2007, 21, 2368-2370.	3.3	86
169	Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. Annals of Hematology, 2007, 86, 887-895.	0.8	19
170	Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 2006, 108, 4178-4186.	0.6	241
171	Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in Acute T cell Leukemias. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 245-254.	2.2	174
172	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. Journal of Clinical Pathology, 2006, 60, 768-772.	1.0	103
173	Prevalence of Fragile Histidine Triad Expression in Tumors from Saudi Arabia: A Tissue Microarray Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1708-1718.	1.1	44
174	JAK Family of Tyrosine Kinases: Its Functions and Alterations in Human Cancer. Current Enzyme Inhibition, 2006, 2, 163-171.	0.3	1
175	Proteosome Inhibitor Treatment Down-Regulates S-Phase Kinase-Associated Protein 2 Causing Inhibition of Proliferation and Induces Apoptosis in Primary Effusion Lymphoma Blood, 2006, 108, 4616-4616.	0.6	0
176	Significance of Ubiquitin Ligase Subunit SKP-2 Proto-Oncogene and Proliferative Marker Ki67 Expression in Diffuse Large B-Cell Lymphoma Blood, 2006, 108, 4343-4343.	0.6	0
177	Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Journal of King Abdulaziz University, Islamic Economics, 2006, 27, 323-8.	0.5	10
178	Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood, 2005, 105, 1669-1677.	0.6	46
179	Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood, 2005, 106, 2436-2443.	0.6	57
180	Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene, 2005, 24, 7022-7030.	2.6	128

#	Article	IF	CITATIONS
181	Role of protein kinase C-δ (PKC-Î) in the generation of the effects of IFN-α in chronic myelogenous leukemia cells. Experimental Hematology, 2005, 33, 550-557.	0.2	37
182	Inhibition of Phosphatidylinositol 3′-Kinase/AKT Signaling Promotes Apoptosis of Primary Effusion Lymphoma Cells. Clinical Cancer Research, 2005, 11, 3102-3108.	3.2	98
183	The PI3' Kinase Pathway in Interferon Signaling. Journal of Interferon and Cytokine Research, 2005, 25, 780-787.	0.5	71
184	Apigenin Induces Apoptosis in Primary Effusion Lymphoma Blood, 2005, 106, 4807-4807.	0.6	0
185	Role of Phosphatidylinositol 3- Kinase/AKT Pathway in Diffuse Large B-Cell Lymphoma Survival Blood, 2005, 106, 4808-4808.	0.6	1
186	Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 147-152.	3.3	152
187	Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochemical and Biophysical Research Communications, 2004, 320, 932-938.	1.0	65
188	Interferon-Î ³ engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Experimental Cell Research, 2004, 295, 173-182.	1.2	79
189	Mechanisms of Type-I Interferon Signal Transduction. BMB Reports, 2004, 37, 635-641.	1.1	36
190	Role of Stat5 in Type I interferon-signaling and transcriptional regulation. Biochemical and Biophysical Research Communications, 2003, 308, 325-330.	1.0	56
191	Activation of Protein Kinase Cl´ by IFN-l ³ . Journal of Immunology, 2003, 171, 267-273.	0.4	124
192	Activation of Protein Kinase Cδ by All-trans-retinoic Acid. Journal of Biological Chemistry, 2003, 278, 32544-32551.	1.6	101
193	Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons. Journal of Biological Chemistry, 2003, 278, 27772-27780.	1.6	114
194	Activation of the p38 Mitogen-activated Protein Kinase Mediates the Suppressive Effects of Type I Interferons and Transforming Growth Factor-β on Normal Hematopoiesis. Journal of Biological Chemistry, 2002, 277, 7726-7735.	1.6	153
195	Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia. Journal of Immunology, 2002, 168, 5984-5988.	0.4	93
196	Protein Kinase C-δ (PKC-δ) Is Activated by Type I Interferons and Mediates Phosphorylation of Stat1 on Serine 727. Journal of Biological Chemistry, 2002, 277, 14408-14416.	1.6	193
197	The CrkL Adapter Protein Is Required for Type I Interferon-Dependent Gene Transcription and Activation of the Small G-Protein Rap1. Biochemical and Biophysical Research Communications, 2002, 291, 744-750.	1.0	36
198	Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochemical and Biophysical Research Communications, 2002, 297, 760-764.	1.0	40

#	Article	IF	CITATIONS
199	Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene, 2002, 21, 1556-1562.	2.6	100
200	Poxvirus Infection Rapidly Activates Tyrosine Kinase Signal Transduction. Journal of Biological Chemistry, 2001, 276, 48371-48375.	1.6	41
201	Engagement of the CrkL adaptor in interferon α signalling in BCR-ABL-expressing cells. British Journal of Haematology, 2001, 112, 327-336.	1.2	35
202	Protein Kinase C-δRegulates Thrombin-Induced ICAM-1 Gene Expression in Endothelial Cells via Activation of p38 Mitogen-Activated Protein Kinase. Molecular and Cellular Biology, 2001, 21, 5554-5565.	1.1	155
203	The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon-α in BCR-ABL-expressing Cells. Journal of Biological Chemistry, 2001, 276, 28570-28577.	1.6	135
204	RANTES Activates Jak2 and Jak3 to Regulate Engagement of Multiple Signaling Pathways in T Cells. Journal of Biological Chemistry, 2001, 276, 11427-11431.	1.6	98
205	Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to All-trans-retinoic Acid. Journal of Biological Chemistry, 2001, 276, 4012-4019.	1.6	146
206	All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. Experimental Hematology, 2000, 28, 826-832.	0.2	8
207	IFN-Î ³ Activates the C3G/Rap1 Signaling Pathway. Journal of Immunology, 2000, 164, 1800-1806.	0.4	68
208	The Rac1/p38 Mitogen-activated Protein Kinase Pathway Is Required for Interferon α-dependent Transcriptional Activation but Not Serine Phosphorylation of Stat Proteins. Journal of Biological Chemistry, 2000, 275, 27634-27640.	1.6	175
209	Interferon-Dependent Activation of the Serine Kinase PI 3′-Kinase Requires Engagement of the IRS Pathway but Not the Stat Pathway. Biochemical and Biophysical Research Communications, 2000, 270, 158-162.	1.0	66
210	Activation of the Akt/FKHRL1 Pathway Mediates the Antiapoptotic Effects of Erythropoietin in Primary Human Erythroid Progenitors. Biochemical and Biophysical Research Communications, 2000, 275, 16-19.	1.0	89
211	Growth Inhibition of a Human Myeloma Cell Line by All-transRetinoic Acid Is Not Mediated Through Downregulation of Interleukin-6 Receptors but Through Upregulation of p21WAF1. Blood, 1999, 94, 251-259.	0.6	49
212	The Proximal Tyrosines of the Cytoplasmic Domain of the β Chain of the Type I Interferon Receptor Are Essential for Signal Transducer and Activator of Transcription (Stat) 2 Activation. Journal of Biological Chemistry, 1999, 274, 4045-4052.	1.6	48
213	Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons. Journal of Biological Chemistry, 1999, 274, 30127-30131.	1.6	211
214	Activation of the Jak-Stat Pathway in Cells That Exhibit Selective Sensitivity to the Antiviral Effects of IFN-beta Compared with IFN-alpha. Journal of Interferon and Cytokine Research, 1999, 19, 797-801.	0.5	28
215	Engagement of Gab1 and Gab2 in Erythropoietin Signaling. Journal of Biological Chemistry, 1999, 274, 24469-24474.	1.6	88
216	Activation of a CrkL-Stat5 Signaling Complex by Type I Interferons. Journal of Biological Chemistry, 1999, 274, 571-573.	1.6	120

#	Article	IF	CITATIONS
217	Defective expression of the SHP-1 phosphatase in polycythemia vera. Experimental Hematology, 1999, 27, 1124-1132.	0.2	48
218	CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Experimental Hematology, 1999, 27, 1315-1321.	0.2	56
219	Interferon Î \pm activates the tyrosine kinase Lyn in haemopoietic cells. British Journal of Haematology, 1998, 101, 446-449.	1.2	13
220	The role of gonadectomy and testosterone replacement on thymic luteinizing hormone-releasing hormone production. Journal of Endocrinology, 1998, 158, 229-235.	1.2	29
221	Identification of a Domain in the Î ² Subunit of the Type I Interferon (IFN) Receptor That Exhibits a Negative Regulatory Effect in the Growth Inhibitory Action of Type I IFNs. Journal of Biological Chemistry, 1998, 273, 5577-5581.	1.6	10
222	Protein Kinase B/Akt Mediates Effects of Insulin on Hepatic Insulin-like Growth Factor-binding Protein-1 Gene Expression through a Conserved Insulin Response Sequence. Journal of Biological Chemistry, 1998, 273, 6482-6487.	1.6	149
223	Interferon-Î \pm Resistance in a Cutaneous T-Cell Lymphoma Cell Line Is Associated With Lack of STAT1 Expression. Blood, 1998, 91, 570-576.	0.6	14
224	Jurkat cell proliferative activity is increased by luteinizing hormone-releasing hormone. Journal of Endocrinology, 1997, 153, 241-249.	1.2	27
225	Interaction of p59fynwith Interferon-Activated Jak Kinases. Biochemical and Biophysical Research Communications, 1997, 235, 83-88.	1.0	56
226	The vav proto-oncogene product (p95 vav) interacts with the Tyk-2 protein tyrosine kinase. FEBS Letters, 1997, 403, 31-34.	1.3	33
227	Interaction of thec-cblProto-oncogene Product with the Tyk-2 Protein Tyrosine Kinase. Biochemical and Biophysical Research Communications, 1996, 225, 833-838.	1.0	31
228	Ethanol-Induced Alterations in the Posttranslational Processing, But Not Secretion of Luteinizing Hormone-Releasing Hormone In Vitro. Alcoholism: Clinical and Experimental Research, 1996, 20, 556-560.	1.4	10
229	Differences in Interferon \hat{I}_{\pm} and \hat{I}^2 Signaling. Journal of Biological Chemistry, 1996, 271, 23630-23633.	1.6	89
230	The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of Insulin Receptor Substrate 2. Journal of Biological Chemistry, 1996, 271, 278-282.	1.6	113
231	Association of the Interferon-dependent Tyrosine Kinase Tyk-2 with the Hematopoietic Cell Phosphatase. Journal of Biological Chemistry, 1995, 270, 18179-18182.	1.6	108
232	Interferon-α Engages the Insulin Receptor Substrate-1 to Associate with the Phosphatidylinositol 3′-Kinase. Journal of Biological Chemistry, 1995, 270, 15938-15941.	1.6	177
233	Interaction of the Transcriptional Activator Stat-2 with the Type I Interferon Receptor. Journal of Biological Chemistry, 1995, 270, 24627-24630.	1.6	40
234	Failure of ethanol metabolites to alter gonadotropin secretion or luteinizing hormone synthesis in vitro. Endocrine Research, 1995, 21, 653-670.	0.6	3

#	Article	IF	CITATIONS
235	Insulin-dependent Tyrosine Phosphorylation of the vav Proto-oncogene Product in Cells of Hematopoietic Origin. Journal of Biological Chemistry, 1995, 270, 7712-7716.	1.6	22
236	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
237	Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis. Frontiers in Oncology, 0, 12, .	1.3	4